+204.6%
RCL vs MRNA
+786.4%
-581.8%
-83.3%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 10y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -2.2% | -2.2% | 0.0% | -2.1% |
| 7D | -8.3% | -12.7% | +4.4% | -7.9% |
| 30D | +2.8% | -20.7% | +23.5% | +3.5% |
| 3M | +3.7% | +46.3% | -42.6% | +2.1% |
| 6M | +18.1% | +305.2% | -287.2% | +8.3% |
| YTD | +8.1% | +561.2% | -553.2% | -3.9% |
| 1Y | +19.7% | +772.1% | -752.4% | +4.8% |
| 3Y | +189.8% | +147.0% | +42.9% | +163.0% |
| 5Y | +281.1% | -26.1% | +307.2% | +237.8% |
| All | +204.6% | +786.4% | -581.8% | +200.4% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 10y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
10y analysis · Full analysis span regression · 6 months rolling